Reglan is the brand name most patients recognize for metoclopramide, a medication prescribed for gastroparesis, severe heartburn that has not responded to other treatment, and nausea tied to chemotherapy or certain procedures. People who take it on a standing basis sometimes worry that a workplace or program drug test could flag it as something it is not. The short answer is that metoclopramide is not a controlled substance and there is no credible published evidence that it cross reacts with a standard immunoassay drug panel. That is a meaningfully different situation from some other antiemetics, particularly promethazine, where a documented interference with amphetamine immunoassay screening does exist in the published literature. This article covers what metoclopramide actually is, how screening and confirmation testing work, what the evidence does and does not show for metoclopramide, and where the real documented reports for antiemetics as a class are found.
What Reglan (metoclopramide) actually is
Metoclopramide works mainly as a dopamine D2 receptor antagonist with some additional effect on serotonin receptors involved in nausea signaling. It speeds gastric emptying, which is the basis for its use in gastroparesis and reflux, and it is also used as an antiemetic. It is a prescription medication but it is not scheduled under the federal Controlled Substances Act and it carries no abuse potential classification in its labeling. The National Institutes of Health's StatPearls chapter on metoclopramide describes its mechanism, approved indications, and the boxed warning on long term use and movement disorder risk that prescribers are expected to discuss with patients, none of which relates to drug testing. The current current prescribing information on the National Library of Medicine's DailyMed label for metoclopramide tablets lists the same indications and does not note any interaction with urine or oral fluid drug screening.
How screening panels and confirmation testing actually work
Rapid cups, dip cards, and oral fluid devices used for workplace and program testing rely on immunoassay chemistry. An immunoassay uses an antibody built to recognize a specific drug or drug class, and it reports a presumptive result based on how strongly a sample binds to that antibody. The tradeoff built into that design is speed and cost against specificity. Occasionally a chemical that is not the target drug has a similar enough shape to trigger the antibody anyway, which is what a true cross reactivity false positive looks like. The National Institutes of Health's StatPearls chapter on urine drug screening describes this limitation directly and explains why any presumptive immunoassay result that matters for an employment or legal decision should be sent for gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS) confirmation, which identifies the exact molecule present rather than a class level signal. Confirmation is the step that separates an actual drug from an assay quirk, and it is also the information a medical review officer needs to evaluate a result against a prescription.
Is there documented cross reactivity evidence for metoclopramide
Based on the available NIH Bookshelf and PubMed Central literature, there is no credible published report of metoclopramide cross reacting with a standard amphetamine, opiate, PCP, benzodiazepine, or THC immunoassay panel. Metoclopramide's structure is built around a benzamide core related to procainamide, which does not resemble the amphetamines, opioids, or other drug classes that standard panels are built to detect, and the StatPearls monograph on metoclopramide does not list drug screening interference among its documented effects. That absence of a published report is not the same as a promise, since individual lab reagents and antibody formulations vary and testing science continues to publish new case reports over time. If a person taking metoclopramide as prescribed receives an unexpected presumptive positive on an unrelated panel, the correct response is confirmation testing and medical review officer contact, not an assumption that the medication explains it without evidence.
Promethazine and other antiemetics: where the documented reports actually are
The picture is different for promethazine, sold under the brand name Phenergan and used for nausea, allergic reactions, and sedation. Promethazine belongs to the phenothiazine chemical class, structurally related to older antipsychotic medications, and that structural resemblance is the documented mechanism behind reported interference. A published review on urine drug screening available through PubMed Central states plainly that phenothiazine antiemetics, specifically naming promethazine and chlorpromazine, are described in the literature as causes of false positive amphetamine immunoassay results, and the same source cites a study in which promethazine produced false positive amphetamine screens in several subjects, with the false positives concentrated among those taking fifty milligrams or more per day. That data is available in the PubMed Central review on urine drug screens for clinical practice. Promethazine's current official labeling, viewable on the DailyMed label for promethazine hydrochloride tablets, does not itself discuss drug screening, which is exactly why the confirmation step and documented literature matter more than the package insert when a presumptive result needs an explanation.
Antiemetics compared
| Medication | Drug class | Documented immunoassay note |
|---|---|---|
| Metoclopramide (Reglan) | Benzamide, dopamine D2 antagonist | No credible published cross reactivity report identified for standard panels |
| Promethazine (Phenergan) | Phenothiazine antihistamine | Documented false positive amphetamine results reported in the published literature, more common at higher daily doses |
| Prochlorperazine (Compazine) | Phenothiazine | Same chemical family as promethazine, but published data specific to this drug is limited, ask the lab which reagent the panel uses |
| Ondansetron (Zofran) | Serotonin 5-HT3 receptor antagonist | No credible published cross reactivity report identified |
| Dimenhydrinate (Dramamine) | Antihistamine | See the dedicated post on dimenhydrinate below for documented notes specific to that medication |
| Meclizine | Antihistamine | No credible published cross reactivity report identified |
The pattern across this table is not random. The antiemetics with a documented interference report are the ones chemically related to phenothiazines or to antihistamines with a structure broad immunoassays were not designed to exclude. Metoclopramide sits outside that chemical family, which lines up with the absence of a published report naming it.
What happens if a screen comes back positive while taking Reglan
Any presumptive positive, whatever the underlying cause, should route through confirmation testing and a medical review officer rather than a direct employment decision based on the screening device alone. Under the federal procedures at 49 CFR Part 40, Subpart G, a medical review officer contacts the individual, asks about current prescriptions, and may contact the prescribing clinician to determine whether a legitimate medical explanation accounts for the result before the result is reported as verified. Programs built on the model the Substance Abuse and Mental Health Services Administration describes on its drug free workplace program page follow the same structure for non federally mandated testing. Since metoclopramide is not expected to trigger any standard panel in the first place, an unexpected presumptive positive in someone taking only Reglan is more likely explained by something else entirely, which is exactly the kind of question confirmation testing and MRO review are built to answer rather than guess at.
What employees and employers should actually do
A person taking metoclopramide for gastroparesis or reflux generally does not need to disclose it in advance of a routine workplace screen, since there is no documented reason it would affect the result. If a presumptive positive does occur for an unrelated reason, current pharmacy records and the prescribing clinician's contact information speed up the medical review officer's verification regardless of what medication is involved. Employers and programs writing policy around antiemetics and other common prescriptions should rely on the documented literature rather than assumptions, and should make sure every presumptive positive, no matter the panel, goes to confirmation before any decision is made. Readers comparing how other common antihistamines and antiemetics are documented on standard panels can see the related posts on whether Dramamine shows up on a drug test and whether chlorpheniramine causes a false positive. Clinics and employers evaluating which screening panels to stock can review device and panel options in the drug test cup collection, and distributors or clinics buying in volume can review case configurations through the wholesale portal.
Frequently asked questions
Does Reglan cause a false positive drug test?
There is no credible published report of metoclopramide, the active ingredient in Reglan, cross reacting with a standard amphetamine, opiate, PCP, benzodiazepine, or THC immunoassay panel. It is not a controlled substance and its chemical structure is unrelated to the drug classes those panels target.
Is metoclopramide a controlled substance?
No. Metoclopramide is a prescription medication but it is not scheduled under the federal Controlled Substances Act and its labeling carries no abuse potential classification.
Does promethazine cause a false positive drug test?
Published literature documents promethazine, a phenothiazine antihistamine sold as Phenergan, producing false positive amphetamine immunoassay results in some patients, more often at higher daily doses. This is a documented interference distinct from metoclopramide, which belongs to a different chemical class with no such published report.
What should someone do if they test positive while taking Reglan?
Disclose the current prescription to the medical review officer and make sure the prescribing clinician can confirm it if contacted. Since metoclopramide is not expected to trigger standard panels, an unexpected positive while taking only Reglan is more likely explained by something else, which confirmation testing and MRO review are designed to identify.
Can a lab tell the difference between an actual drug and a false positive interference?
Yes. Gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS) confirmation testing identifies the specific molecule present, which separates a true positive from an immunoassay cross reactivity result. A medical review officer uses that confirmed result, along with prescription documentation, to make a final determination.
Are all antiemetics treated the same on drug test panels?
No. Documented interference reports concentrate in the phenothiazine class, which includes promethazine, not in every antiemetic. Metoclopramide, ondansetron, and meclizine do not have the same published documentation, which is why each medication should be evaluated on its own chemistry rather than grouped together as a class.
This article is general information about drug testing science and is not medical or legal advice. Anyone with questions about a specific prescription, test result, or workplace policy should talk to their prescribing clinician, their employer's medical review officer, or legal counsel.
